A prospective surveillance study in haemophilia B patients following a population switch to recombinant factor IX (nonacog gamma)-Reference-Cited by-同舟云学术

A prospective surveillance study in haemophilia B patients following a population switch to recombinant factor IX (nonacog gamma)

Published:2021-02-08 Issue:4 Volume:27 Page:
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Dubé Evemie¹,Merlen Clémence¹,Bonnefoy Arnaud¹,Gauthier Julie²³,Castilloux Jean‐François⁴,Cloutier Stéphanie⁵,Demers Christine⁵,Sabapathy Christine A.⁶,St‐Louis Jean¹⁷^ORCID,Vézina Catherine⁶,Warner Margaret⁶,Rivard Georges‐Étienne¹^ORCID

Affiliation:

1. Division of Hematology‐Oncology Department of Pediatrics CHU Sainte‐Justine Montréal QC Canada

2. Molecular Diagnostic Laboratory CHU Sainte‐Justine Montréal QC Canada

3. Department of Pediatrics CHU Sainte‐JustineUniversité de Montréal Montréal QC Canada

4. Centre Hospitalier Universitaire de SherbrookeUniversité Sherbrooke Sherbrooke QC Canada

5. Hôpital de l’Enfant JésusCHU de Québec Québec QC Canada

6. Montreal Children’s HospitalMcGill University Health Center Montréal QC Canada

7. Hôpital Maisonneuve‐Rosemont Montréal QC Canada

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14273

Reference10 articles.

1. New developments in the management of moderate‐to‐severe hemophilia B.J;Nazeef M;Blood Med,2016

2. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates

3. Recombinant Factor IX Recovery and Inhibitor Safety: A Canadian Post-licensure Surveillance Study

4. Safe switching from a pdFIX (Immunine®) to a rFIX (Bax326)

5. Recent trial results in recombinant coagulation factors for the treatment of hemophilia B